28143658|t|Molecular docking simulation and anticancer assessment on human breast carcinoma cell line using novel bis(1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile) and bis(1,4-dihydropyrazolo[4',3':5,6]pyrano[2,3-b]pyridine-6-carbonitrile) derivatives
28143658|a|An efficient route for the synthesis of novel bis(1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile) derivatives is reported. The synthetic pathway involves one pot, synthesis of bis-aldehydes, malononitrile, and pyrazolone in the presence of pyridine. The anticancer activity of the synthesized products against MCF7, HEPG2, and A549 cell lines was assessed. Docking studies were performed and indicated the best binding mode compared to the standard ligand sorafenib.
28143658	0	28	Molecular docking simulation	T062	UMLS:C3494273
28143658	33	54	anticancer assessment	T058	UMLS:C0920425
28143658	58	63	human	T204	UMLS:C0086418
28143658	64	80	breast carcinoma	T038	UMLS:C0678222
28143658	81	90	cell line	T017	UMLS:C0007634
28143658	103	155	bis(1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile)	T103	UMLS:C1254351
28143658	160	243	bis(1,4-dihydropyrazolo[4',3':5,6]pyrano[2,3-b]pyridine-6-carbonitrile) derivatives	T103	UMLS:C1254351
28143658	257	262	route	T082	UMLS:C0449444
28143658	290	354	bis(1,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile) derivatives	T103	UMLS:C1254351
28143658	421	434	bis-aldehydes	T103	UMLS:C0029224
28143658	436	449	malononitrile	T103	UMLS:C0057889
28143658	455	465	pyrazolone	T103	UMLS:C0072664
28143658	485	493	pyridine	T103	UMLS:C0034251
28143658	499	518	anticancer activity	T058	UMLS:C0920425
28143658	555	559	MCF7	T017	UMLS:C0596890
28143658	561	566	HEPG2	T017	UMLS:C2717940
28143658	572	587	A549 cell lines	T017	UMLS:C4277577
28143658	602	617	Docking studies	T170	UMLS:C3494274
28143658	701	710	sorafenib	T103	UMLS:C1516119